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Abstract: Both age related macular degeneration (AMD) and light induced retinal damage share the
common major role played by oxidative stress in the induction/progression of degenerative events.
Light damaged (LD) rats have been widely used as a convenient model to gain insight into the
mechanisms of degenerative disease, to enucleate relevant steps and to test neuroprotectants. Among
them, saffron has been shown to ameliorate degenerative processes and to regulate many genes and
protective pathways. Saffron has been also tested in AMD patients. We extended our analysis to a
possible additional effect regulated by saffron and compared in AMD patients a pure antioxidant
treatment (Lutein/zeaxanthin) with saffron treatment. Methods: Animal model. Sprague-Dawley
(SD) adult rats, raised at 5 lux, were exposed to 1000 lux for 24 h and then either immediately sacrificed
or placed back at 5 lux for 7 days recovery period. A group of animals was treated with saffron.
We performed in the animal model: (1) SDS-PAGE analysis; (2) Western Blotting (3) Enzyme activity
assay (4) Immunolabelling; in AMD patients: a longitudinal open-label study 29 (±5) months in
two groups of patients: lutein/zeaxanthin (19) and saffron (23) treated. Visual function was tested
every 8 months by ERG recordings in addition to clinical examination. Results: Enzymatic activity
of MMP-3 is reduced in LD saffron treated retinas and is comparable to control as it is MMP-3
expression. LD treated retinas do not present “rosettes” and microglia activation and migration is
highly reduced. Visual function remains stable in saffron treated AMD patients while deteriorates
in the lutein/zeaxanthin group. Conclusion: Our results provide evidence of an additional way of
action of saffron treatment confirming the complex nature of neuroprotective activities of its chemical
components. Accordingly, long term follow-up in AMD patients reveals an added value of saffron
supplementation treatment compared to classical antioxidant protocol.
Keywords: oxidative stress; age related macular degeneration; light induced damage; matrix
metalloproteinases; saffron
1. Introduction
Retinal tissue, and particularly photoreceptors, has an extremely high metabolic rate. As a
consequence, the production of ROS reaches high levels in physiological conditions. A unique source of
ROS generation is due to light, which is the essential stimulus to provide visual information. An efficient
homeostatic system maintains the production of ROS under control [1]. With age or in pathological
conditions, the equilibrium is disrupted, and a negative feedback takes place. Specifically, the reduced
removal of free radicals might induce dysmetabolic processes; proteins are abnormally folded and
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aggregate to give rise to intra and extracellular deposits, which, in turn, produce more ROS. At this
stage, an inflammatory process starts [1–3]. The retina presents a privileged immune-environment and
a peculiar population of glial cells, specifically: (1) microglia that are resident in the inner retina and
move to outer retina only in pathological conditions; (2) macroglia (astrocytes and Muller cells). Muller
cells are probably modified astrocytes playing a unique role in the retina and are pivotal in reactive
retinal responses to any stress. An intriguing question is when the link between oxidative stress and
neuroinflammation becomes active. To understand at which level the production of ROS activates a
glia response is an important issue. Even if knowledge is not complete, the sequence of events has been
progressively clarified in recent papers [4,5]. The first consequence of Muller cells’ activation is the
release of cytokines and trophic factors acting at different levels [6]. Microglia are activated and migrate
to the outer retina in an effort to eliminate debris and support photoreceptor function. Unfortunately
this event gives rise to neuroinflammatory processes that transform a supportive role of microglia
into a toxic one [7,8]. Interestingly, as reported in a recent review [9], all neurodegenerative diseases
(Alzheimer, Parkinson, SLA etc.) share a common feature that is the accumulation of misfolded proteins
and activation of microglia. As a consequence, a vicious cycle of inflammation starts that accelerates
the progression of the pathology. We used a convenient model of retinal degeneration induced
by oxidative stress to understand the sequence of events and test neuro-protective agents [10–12];
including saffron [10,11,13]. To induce retinal neurodegeneration, albino rats were exposed to high
intensity white light. This model has been validated in many experiments [10–15]. The initial
event is phototoxic [16], inducing peroxidation of membrane lipids, starts in a specific dorsal area
named the “hot spot” [10,14] and triggers a series of events leading to the death of photoreceptors.
The degeneration progresses in time and space following the activation of a glial reaction, cytokines
release, and neuroinflammation [7,8,17]. A morphological characteristic of the outer nuclear layer
during the progression of the degenerative process is the presence of “rosettes” (see Figure 1). Among
the genes modulated by light exposure [18], there are matrix metalloproteinase-3 (MMP-3), metallothionein
2A (Mt2A), and TIMP metalloproteinase inhibitor 1 (TIMP-1) whose activation was increased by light.
Matrix metalloproteinase-3 (MMP-3) is a member of the matrix metalloproteinases, zinc-dependent
endoproteases, able to degrade all the components of extracellular matrix and so could play a critical
role in the dysregulation of extracellular matrix leading to the appearance of “rosettes”. Among human
visual diseases, age related macular degeneration (AMD) and Stargardt, although different in their
origin, share the common dependence on oxidative stress [19]. Age related macular degeneration
(AMD) is a degenerative disease centered on the macula with a strong involvement of retinal pigment
epithelium (RPE), Bruch’s membrane and photoreceptors. AMD is a complex disorder that affects
primarily the fovea rich in cone photoreceptors. It is a late-onset disease resulting from the interplay
of age and multiple genetic susceptibility genes and environmental factors, but its pathogenesis
remains largely unresolved. In any case the relevance of oxidative stress and neuroinflammation
in the development and progression of the disease is unquestionable. Abnormal production of free
radicals initially leads to an extracellular deposit of waste molecules (drusen) in RPE that eventually
induce malfunction in RPE and death of photoreceptors. Although at present the correlation between
ROS production and AMD development is not completely understood, it is clear that many factors
contribute to increase ROS production (see ref. [1]) and targeting free radicals for treating AMD became
a must. Particularly for dry AMD, a protocol was standardized in early 2000 and gave rise to the
AREDS treatment [20]. The driving idea was to use antioxidants to interfere with the progression of
the disease. The original protocol was re-visited in the AREDS2 and some components of the original
composition have been changed [21,22]. Nevertheless, the efficacy was verified by a long-term study
showing that the supplement was able to slow down the progression of intermediate AMD. Recently
natural products with antioxidant capacity have been tested. Compared to the others, saffron appeared
very promising in slowing down the progression of AMD [23–28]. Interestingly, the ways of action
activated by saffron are complex and not limited to a simple antioxidant activity [18,26,29,30] and it
was supposed that saffron treatment might be able to activate a mechanism of tissue resilience [31],
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meaning that low doses and long treatment increase the probability of a positive outcome. Microarray
experiments [18] have shown that saffron is able to modulate gene expression modified by retinal
induced damage. Here we report data showing that saffron treatment modulates metalloproteinase
expression and enzymatic activity and reduces external matrix dis-organization. These results confirm
and extend our previous data [13,18,29,30] showing that the efficacy of saffron treatment is not only due
to the antioxidant characteristics of its chemical components (mainly crocins) but activates complex
ways of action able to modulate negative feed-back. This idea has been also tested in human subjects
by a retrospective analysis performed in patients treated either with the AREDS protocol or saffron for
a period of 29 months. The results confirm our hypothesis that a higher efficacy of saffron treatment is
probably related to the activation of multiple pathways.
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Figure 1. Nuclear staining (DAPI) of Control (left), Light damaged (center) and Light damaged 
treated with Saffron (right). Rosettes in LD are indicated with arrows. Images are taken in 
corresponding dorsal regions near the “hot spot”. ONL = outer nuclear layer; INL = inner nuclear 
layer; RGC = retinal ganglion cell layer. 
i r . clear staining (DAPI) of Control (left), Light damaged (c nter) and Light damaged treate
with Saffron (right). Rosettes in LD are dicated w th arrows. Images are taken in co responding
do sal regio s nea the “hot spot”. ONL = uter nuclear layer; INL = inne nuclear layer; RGC = retinal
ganglion cell layer.
2. Materials and Methods
All animal experiments were authorized by the Ministry of Health (authorization number 83/96-A
of 29/11/1996). In addition, all procedures were in line with the ARVO Statement for the Use of Animals
in Ophthalmic and Vision Research and were approved by the local Ethical Committee of the University
of L’Aquila.
Experimental design: A total of 50 albino rats was used for these experiments, divided in
5 experimental groups:
- Healthy control (n = 10) that received neither retinal damage, nor treatment;
- Light damaged no recovery group (n = 10) that received retinal damage but no treatment and were
sacrificed immediately after light damage to perform SDS-page, western blotting, biochemical
assay and MMP-3 immunostaining experiments;
- Light damaged with recovery (n = 10) that received retinal damage but no treatment and were
sacrificed 7 days after the exposure to the light damage;
- Saffron treated + Light damaged no recovery group (n = 10) that received retinal damage and
saffron treatment and were sacrificed immediately after light damage to perform SDS-page,
western blotting, biochemical assay and MMP3 immunostaining experiments;
- Saffron treated + Light damaged with recovery (n = 10) that received retinal damage and saffron
treatment and were sacrificed 7 days after the exposure to the light damage;
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Light damage: Adult albino rats (2 months old) born and raised in our colony at 5 lux mean
luminance were moved singularly into a cage with cold-white fluorescent lights placed at the top
and at the bottom to ensure an iso-luminance environment (1000 lux) inside the cage. The litter was
removed from the cage to prevent rats hiding their eyes from the light. Light exposure started at
the beginning of the day in the animal house, immediately after the 12 h of darkness. Animals were
consecutively exposed to 1000 lux light for 24 h and immediately placed back into normal cages and
re-stabled in normal conditions for the recovery group. A group of animals was sacrificed immediately
after light exposure for SDS-page, western blotting, biochemical assay and MMP-3 immunostaining.
Saffron Treatment: The animals belonging to the “LD + saffron” group were treated with saffron
(patent: W02015/145316 which defines the best ratio among crocins) (1 mg/kg/day) soaked in tap
water as diet supplementation, for 21 days before the light damage. Saffron treatment uninterruptedly
continued during the whole recovery period up to the sacrifice of the animals (7 days after LD).
Morphological Analysis: Eyes were explanted and fixed in 4% paraformaldehyde fixative buffer
at 4 ◦C for 24 h. After several rinses in 0.1 M phosphate-buffered saline (PBS), eyes were cryoprotected
with an overnight immersion in 15% sucrose solution. After embedding with mounting medium
(Tissue Tek OCT compound; Sakura Finetek, Torrance, CA, USA) and snap freezing in liquid nitrogen,
cryo-sections were cut at 20 µm (CM1850 Cryostat; Leica, Wetzlar, Germany). Eye sections were
collected from the center to periphery with dorsal-ventral orientation. Section were finally mounted
on gelatin and poly-l-lysine coated slides.
Immunohistochemistry: Retinal sections were washed with 0.1 M PBS and incubated in 10%
normal goat serum (Sigma, St. Louis, MO, USA) or 0.75% horse serum (Sigma, St. Louis, MO, USA) in
0.1 M PBS for 1 h at room temperature, to block non-specific binding, before incubation with the primary
antibody overnight at 4 ◦C: Goat-MMP-3 (AbCAM, Cambridge, UK) and rabbit polyclonal IBA-1
(AbCAM, Cambridge, UK). Sections were washed in 0.1 M PBS, then incubated with the appropriate
secondary antibody for 2 h at 37 ◦C. Immunofluorescence was viewed using a Zeiss laser scanning
microscope. The data quantification represented in the figures has been collected from at least one
retina section per animal for each group.
10% SDS-PAGE: analysis was performed on retinal protein extract according to Laemmli [32].
The protein bands were stained with Blue Coomassie R-250.
Western Blotting: For each sample, 30 mg protein was resolved by electrophoresis on 12% sodium
dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) and was transferred onto PVDF
membranes (GE Healthcare, Chicago, IL, USA). Non-specific signals were subtracted by placing blots
for 1 h at room temperature incubation in a mix of 150 mM NaCl, 10 mM Tris (pH 8.0, 5% milk
(Bio-rad, Hercules, CA, USA) and 0.1% Tween 20 (TBST). Membranes were incubated overnight
at 4 ◦C with goat polyclonal secondary antibodies to MMP-3 (ab18898, AbCAM, Cambridge, UK).
Membranes were washed with TBST and then incubated for 1 h at room temperature with anti–goat
peroxidase-linked secondary antibodies (ab6741, AbCAM, Cambridge, UK) and with anti-rabbit
peroxidase-linked secondary antibodies (sc-2030, Santa Cruz Biotechnology, Dallas, TX, USA). Protein
signals were detected with a chemiluminescent reagent (ECL, West Bengal, India; Super Signal West
Pico Chemiluminescent substrate; Pierce) followed by the exposure to Chemidoc (Bio-rad). Membranes
were probed with an anti–α-actinin polyclonal antibody (PA5-17308, Thermo Scientific, Waltham, MA,
USA) as housekeeping gene, followed by incubation with an anti–rabbit peroxidase-linked secondary
antibody (sc-2030, Santa Cruz Biotechnology). Densitometric analysis was performed (Image Lab
software version 4.0) on scanned files. Densitometric values obtained for MMP-3 were normalized
with respect to α-actinin levels in the same blot.
Enzyme activity: individual rat retinas were homogenized in 200 µL of ice-buffer (Tris 20 mM,
10 µg/mL leupeptin and aprotinin, 2 mM PMSF, Triton 0.5%, pH 7.5) for 30 min; the samples were
centrifuged at 15,000× g for 20 min and the supernatants were collected for protein concentration assay
and activity measurements. MMP-3 activity was measured using a specific 5 µM MMP-3 fluorogenic
substrate, MOCAc-Arg-Pro-Lys-Pro-Val-Glu-Nva-Trp-Arg-Lys(Dnp)-NH2 (Calbiochem) in 50 mM
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sodium acetate buffer, pH 5.5, for 30 min at 37 ◦C. The fluorescence assays were performed at 325 nm
excitation and 393 nm emission using a Perkin Elmer LS50B luminescence spectrometer. The results
were expressed as units of fluorescence/min·mg of total proteins.
Statistical Analysis: Statistical analysis was performed using the commercial package Prism 7
(Graphpad Software). In all analyses we compared Healthy, Saffron treated and Light damaged groups,
applying a Two-way ANOVA test, followed by Bonferroni post-hoc tests.
AMD patients: Short-term clinical trial of saffron was approved by the Ethics Committee and the
protocol was published in “clinicaltrials.gov” NCT00951288. Long-term clinical follow-up of AMD was
approved by the Ethics Committee of the Università Cattolica (title: Clinical and genetic biomarkers of
AMD) and written, informed consent was obtained from each patient after the procedures and methods
of the study were fully explained. fERGs were recorded in response to a sinusoidally modulated
(41 Hz) uniform field presented to the macular region (18◦) at different modulations between 16.5%
and 93.5% on a light-adapting background. For each fERG response, the Fourier-isolated fundamental
harmonic component was measured and the noise level at this component estimated. Main outcome
measures were fERG amplitude (in microV), signal-to-noise amplitude ratio (S/N in dB) and phase
(in degrees).
3. Results
3.1. Light Induced Retinal Degeneration
In agreement with previous results (see ref. [26]), light exposure induces a localized damage
in the dorsal retina which is highly reduced by saffron pretreatment (Figures 1 and 2). A week
after the induction of damage, the progression of the neurodegenerative events is reduced as is
microglia activation (Figure 2A–C). The number of Iba-positive cells in the outer nuclear layer (ONL)
is significantly less in saffron treated LD retinas compared to untreated LD (Figure 2D). The width of
the ONL looks preserved in agreement with a reduction in photoreceptor death as has already been
shown [13] (see ref. [26]). In addition, the structure of the ONL remains highly invariant. Figure 1
shows three examples taken in corresponding retinal regions close to the “hot spot”; it is possible to
note a greater number of photoreceptor layers in treated retina and the absence of “rosettes” which are
clearly visible in untreated retina and are due to the dysregulation of extracellular matrix.
To verify the hypothesis that disorganization of extracellular matrix is strictly related to
metalloprotease activity, we tested retinas explanted from LD albino rats treated and untreated
with saffron according to the protocol already described [13]. We started our analysis by checking the
proteolitic activity in degenerating retinas and as reported in Figure 3 we found that saffron was able
to maintain protein structure in a range comparable to the healthy control. Figure 3 shows SDS-page
analysis performed on retinal lysates obtained from: (1) normal control albino rat; (2) LD rat; (3) saffron
treated LD rats. It can be easily noted that proteolytic activity is present in degenerating retina (line 2)
after acute exposure to light. In saffron treated LD rats, the proteolitic activity is absent and a complete
pattern is shown as in lane 1 (control), suggesting a maintenance in protein structure.
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We performed western blot analysis as well as enzymatic activity assay and immunostaining
to verify whether a relationship exists among light damage, saffron supplementation and MMP-3
regulation. Immunoblot analysis showed that MMP-3 expression was upregulated during light
damage, and this increase was suppressed by treatment with saffron (Figure 4). The reduction was
statistically significant.Antioxidants 2019, 8, x FOR PEER REVIEW 8 of 14 
 
Figure 4. Western blot analysis of MMP-3 protein level in control, untreated and saffron treated light 
damaged retinas. The MMP-3 densitometric analysis normalized for α-Actinin shows that MMP-3 
protein in saffron treated light damaged retinas is similar to that of control, and significantly reduced 
compared to the light damaged group. The mean ± SE is reported. (* = p < 0.05). 
The enzymatic activity was tested in LD retinas of treated and untreated rats and control 
unstressed animals. Our data showed that in treated animals the activity of MMP-3 decreases 
significantly (Figure 5). 
Figure 4. estern blot analysis of -3 r tei le el i c tr l, treate s ffron treated light
da a retinas. - e it l i r li f r - cti i s s that P-3
protein in saffron treated light da aged retinas is si ilar to that of control, an si ificantly reduced
co pared to the light da aged group. The ean ± . . ).
e enz atic acti it as teste i reti as of treate an untreate rats an control
stresse a i als. r ata s e t at i treate a i als t e acti it f -3 decreases
significantly (Figure 5).
Antioxidants 2019, 8, 224 8 of 13
Antioxidants 2019, 8, x FOR PEER REVIEW 9 of 14 
 
Figure 5. MMP-3 activity measured in retinal extracts of untreated rats (healthy control); rats 
exposed to light damage (Light Damaged) and rats treated with saffron and exposed to light damage 
(Light Damaged + Saffron). Results are expressed as the mean ± S.E of four independent experiments. 
* p < 0.02. 
To define the retinal localization of MMP-3, an antibody immunofluorescence analysis was 
performed. MMP-3 immunoreactivity was detected in thin, radial processes in the inner nuclear 
layer of the superior retina, likely in the Müller cells, in both groups exposed to light damage (Figure 
6), but in treated animals the number of processes decreased. 
 
Figure 6. MMP-3 immunoreactivity in the different experimental models: Healthy control (Left), 
Light Damaged (Center) and Light Damaged with saffron supplementation (Right). Animals were 
sacrificed at the end of light exposure. OS = photoreceptor outer segments; ONL = outer nuclear 
layer; OPL = outer plexiform layer; INL = inner nuclear layer; IPL = inner plexiform layer; GCL = 
retinal ganglion cell layer. 
Figure 5. MMP-3 activity measured in retinal extracts of untreated rats (healthy contr l); rats exposed
to light damage (Light Dama ed) nd rats treated with saffron and exposed to light damage (Light
Damaged + Saffron). Results are expressed as the mean ± S.E of four independent experiments.
* p < 0.02.
To define the retinal localization of MMP-3, an antibody immunofluorescence analysis was
performed. MMP-3 immunoreactivity was detected in thin, radial processes in the inner nuclear layer
of the superior retina, likely in the Müller cells, in both groups exposed to light damage (Figure 6),
but in treated animals the number of processes decreased.
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Figure 6. MMP-3 immunoreactivity in the different experimental models: Healthy control (Left), Light
Damaged (Center) and Light Damaged with saffron supplementation (Right). Animals were sacrificed
at the end of light exposure. OS = photoreceptor outer segments; ONL = outer nuclear layer; OPL =
outer plexiform layer; INL = inner nuclear layer; IPL = inner plexiform layer; GCL = retinal ganglion
cell layer.
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3.2. Long-Term Treatment in AMD Patients (AREDS and Saffron)
Results obtained in two groups of patients supplemented either with Lutein/Zeaxanthin or saffron
are reported in Figure 7. Visual function was measured using a standardized protocol [23]. Clinical
examination and Focal (macular (18◦)) electroretinogram (fERG) were recorded to estimate flicker
sensitivity every 8 months over a follow-up period of 29 (±5) months. Figure 7 reports the mean
change of fERG amplitude with respect to base-line. Patients treated with the AREDS protocol [20]
(Lutein/Zeaxanthin) present a deterioration of retinal function whereas saffron treated patients showed
quite a stable response over time; altogether these results suggest that saffron is more powerful in
slowing down the progression of the disease compared to the widely employed standard AREDS
supplement. Clearly, further studies on a large cohort of patients will be needed to confirm these
preliminary data. Moreover, in this study, we did not include AMD patients untreated control
group. We know from several previous natural history studies (i.e., [33]) that intermediate AMD may
progress in a variable time span to severe visual loss. There are several risk factors that are involved,
including genetics and environmental factors, and may determine the rate of progression. Therefore,
a straightforward comparison between the treated patients and the historical controls or the untreated
controls was not possible in the current study.
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Figure 7. fERG Log amplitude change from baseline is reported for two groups of patients treated either
with Saffron or Lutein/Zeaxanthin. Box plots showing the mean (closed squares), median (horizontal
line), interquartile range (box), upper and lower 95% percentiles (error bars), upper and lower 99%
percentiles (blue square and triangle, respectively) of the distribution of the fERG log amplitude changes
from baseline in Saffron- and Lutein/Zeaxanthin-treated AMD patients. The difference between the
two groups was highly significant (independent t-test).
4. Discussion
The main results reported in this paper show that saffron treatment presents high efficiency in
reducing the effects of neurodegenerative processes both in an animal model and human disease
where oxidative stress and neuroinflammation are heavily involved. To our knowledge this is the first
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functional analysis of a comparative follow-up in two groups of AMD patients treated with two different
protocols. Data obtained support the hypothesis of an added value of saffron treatment compared
to the classical pure antioxidant. Results obtained in animal models and cell culture suggested this
possibility. The sequence of events triggered by the production of free radical scavengers has been
partially clarified and the role played by neuroinflammation has been extensively discussed [4,8,9,34]
although many questions did not receive a clear answer. Accordingly, it is becoming a “must” in
clinical practice to block negative feedback. Muller reactive gliosis and activation of microglia are the
first signs of a retinal response to any stress and represent the first targets for neuroprotective strategies.
Many therapeutic approaches have been introduced in clinical practice and saffron appeared very
promising in retinal diseases associated with oxidative stress (and consequently neuroinflammation)
like AMD and Stargardt. Clinical trials [23,27,28] and long term-follow up [24,25] provided evidence of
the efficacy of saffron treatment in coping with AMD disease, while experiments in LD animal models
and cell cultures have showed the complexity of saffron activity [10,11,13,18,26,29,30]. Data reported
in this paper suggest that saffron modulates a way of action not yet explored that might cope with
extracellular matrix disorganization inducing morphological features observed in both animal and
human degenerating retinas. Muller cells are the first to be activated in response to any stress (oxidative
in our model) and apparently, they directly control a variety of metabolic pathways including the
stability of retinal tissue. They do so also by maintaining under control the expression/activation
of metalloproteinases as suggested by present data. Activation of the matrix metalloproteinases is
pivotal in the remodeling of the extracellular matrix and MMP-3 is usually involved in such activation
mechanisms. The presence of other MMPs, namely MMP-2 and -9, in their inactive forms has been
reported in the human Bruch’s membrane [35]. It can be speculated that MMP-3 released from the
vesicle-like structure in the Muller glia, after light induction, could induce extra-direct proteolytic
activity and/or a specific activation of other proteases such MMP-2 and -9. The analysis of the
proteolyzed cleavage site fragment could give an answer to this behavior. Eventually, the stability
of retinal tissue becomes compromised leading to the appearance of “rosettes”, retinal dysfunction
and death. Saffron treatment looked very efficient in maintaining retinal morphology and reducing
metalloproteinase activation, suggesting a new way of action in addition to the ones already clarified
and the antioxidant role played directly by chemical components, mainly crocins [36]. It remains
an open question whether metalloproteinase regulation and stability of retinal tissue are directly
related (interdependent). Results obtained in AMD patients give support to the hypothesis of multiple
mechanisms of action. Visual performance in saffron treated patients’ remains stable while deteriorates
in patients treated with the AREDS protocol. The main difference between the two protocols is that
AREDS is a mixture of antioxidants while saffron seems to cope also with down-stream events including
neuro-inflammation, confirming the hypothesis of an added value of saffron treatment with respect
to pure antioxidant treatment. Recently, Stone et al. [31] pointed out the idea of “acquired resilience”
which can be generated by a tissue response to low stress levels which may induce an organized
protective response. Saffron might promote resilience in response to oxidative and inflammatory
stresses. A large number of clinical trials is necessary to confirm this promising result.
5. Conclusions
The current paper presents data supporting the hypothesis that saffron, with its complex
chemical composition, may cope with neurodegenerative retinal diseases. The initial event is always
multifactorial but oxidative stress plays a pivotal role at various levels including the activation of
neuroinflammatory pathways. Saffron acts at different levels directly as an antioxidant but also by
regulating many genes and protein synthesis. Neuronal death, neuroinflammation and morphological
disorganization are reduced, and the progression of the degenerative pathology is slowed down.
Data comparing two treatments in patients seems to support the hypothesis of an added value in
saffron treatment.
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ROS reactive Oxygen Species
MMP-3 matrix metalloproteinase-3
Mt2A metallothionein 2A
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AMD age related macular degeneration
RPE retinal pigmented epithelium
AREDS Age-Related Eye Disease Study
fERG focal electroretinogram
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